Why Aria Pharmaceuticals is upbeat about two novel IPF treatment candidates September 24, 2021 In the News Small molecule drug developer Aria Pharmaceuticals (Palo Alto, Calif.) recently revealed that two investigational treatments for idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated promising results in preclinical research. READ MORE